Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.71 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291342 | 0.87 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL3535170 | 0.84 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL3595426 | 0.84 | P2RX7 (1.00) | P2RX7DRD2 | |
| SCHEMBL3596097 | 0.82 | P2RX7 (1.00) | P2RX7DRD2 | |
| SCHEMBL3586477 | 0.82 | P2RX7 (1.00) | P2RX7DRD2 | |
| SCHEMBL3593483 | 0.78 | P2RX7 (0.84) | P2RX7DRD2 | |
| SCHEMBL3292110 | 0.77 | P2RX7 (0.44) | P2RX7ACHEPDE10APOLB | |
| SCHEMBL253634 | 0.75 | MEN1 (0.55) | TRPV1POLBDRD2 | |
| SCHEMBL3533100 | 0.75 | DGAT2 (0.48) | ACHETRPA1TRPV1CNR2POLB | |
| SCHEMBL3287405 | 0.74 | PDE10A (0.51) | ACHEPDE10ATRPA1TRPV1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | claimed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | claimed |
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885ACHE 1881/4885PDE10A 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.